Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-α) | Bentham Science
Login Register Cart 0
Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-α)

Author(s): Sagarika Biswas*

Volume 14, Issue 1, 2019

Page: [85 - 90] Pages: 6

DOI: 10.2174/1574885513666180503145352

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Rheumatoid Arthritis (RA) is an autoimmune disorder of symmetric synovial joints which is characterized by the chronic inflammation with 0.5-1% prevalence in developed countries. Presence of persistent inflammation is attributed to the major contribution of key inflammatory cytokine and tumour necrosis factor- alpha (TNF- α). Recent drug designing studies are developing TNF-α blockers to provide relief from the symptoms of the disease such as pain and inflammation. Available blockers are showing certain limitations such as it may enhance the rate of tuberculosis (TB) occurrence, lymphoma risk, cost issues and certain infections are major concern. Discussed limitations implicated a need of development of some alternative drugs which exhibit fewer side effects with low cost. Therefore, we have identified anti-inflammatory compounds in an underutilized fruit of Baccaurea sapida (B.sapida) in our previous studies. Among them quercetin have been identified as the most potent lead compound for drug designing studies of RA.

Methods: In the present article, characterization of quercetin has been carried out to check its drug likeliness and molecular docking study has been carried out between TNF- α and quercetin by using AutoDock 4.2.1 software. Further, inhibitory effect of B. sapida fruit extract on RA plasma has been analysed through immunological assay ELISA.

Results: Our in-silico analysis indicated that quercetin showed non carcinogenic reaction in animal model and it may also cross the membrane barrier easily. We have studied the ten different binding poses and best binding pose of TNF-α and quercetin showed -6.3 kcal/mol minimum binding energy and 23.94 µM inhibitory constant. In addition to this, ELISA indicated 2.2 down regulated expression of TNF-α in RA compared to control.

Conclusion: This study may further be utilized for the drug designing studies to reduce TNF-α mediated inflammation in near future. This attempt may also enhance the utilization of this plant worldwide.

Keywords: Underutilized fruit, molecular docking, rheumatoid arthritis, TNF-α blockers, antiinflammatory, quercetin.

« Previous
Graphical Abstract

[1]
Rodriguez-Rodriguez L, Lamas JR, Varade J, et al. Combined influence of genetic and environmental factors in age of rheumatoid arthritis onset. Rheumatol Int 2012; 32: 3097-102.
[2]
Mellado M, Martínez-Muñoz L, Cascio G, Lucas P, Pablos JL, Rodríguez-Frade JM. T cell Migration in Rheumatoid Arthritis. Front Immunol 2015; 6: 384.
[3]
Postal M, Appenzeller S. The role of Tumor Necrosis Factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56: 537-43.
[4]
Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
[5]
Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008; 9: 52.
[6]
Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 2012; 5: v38-47.
[7]
Sharma A, Sahu S, Kumari P, Gopi SR, Malhotra R, Biswas S. Genome-wide identification and functional annotation of miRNAs in anti-inflammatory plant and their cross-kingdom regulation in Homo sapiens. J Biomol Struct Dyn 2016; 29: 1-12.
[8]
Christopher AF, Kaur RP, Kaur G, Kaur A, Gupta V, Bansal P. MicroRNA therapeutics: Discovering novel targets and developing specific therapy. Perspect Clin Res 2016; 7: 68-74.
[9]
Gopi SR, Sharma A, Biswas S. Identification of the potential inhibitor for C. pneumonia derived HSP60 from medicinally important plants; A therapeutic approach for reducing inflammation in CAD. Innov Approach Stem Cell Res Cancer Biology Appl Biotechnol 2014; 1: 119.
[10]
Mann S, Sharma A, Biswas S, Gupta RK. Identification and molecular docking analysis of active ingredients with medicinal properties from edible Baccaurea sapida. Bioinformation 2015; 11: 437-43.
[11]
Goyal KA, Mishra T, Sen A. Antioxidant profiling of Latkan (Baccaurea ramiflora Lour.) wine. Indian J Biotechnol 2013; 12: 137-9.
[12]
Li Y, Yao J, Han C, et al. Quercetin, Inflammation and Immunity. Nutrients 2016; 8: 167.
[13]
Chen S, Jiang H, Wu X, Fang J. Therapeutic effects of quercetin on inflammation, obesity, and type 2 diabetes. Mediators Inflamm 2016; 2016: 9340637.
[14]
Huang J, Zhu M, Tao Y, et al. Therapeutic properties of quercetin on monosodium urate crystal-induced inflammation in rat. J Pharm Pharmacol 2012; 64: 1119-27.
[15]
Maunz A, Gütlein M, Rautenberg M, Vorgrimmler D, Gebele D, Helma C. Lazar: A modular predictive toxicology framework. Front Pharmacol 2013; 4: 38.
[16]
Paramashivam SK, Elayaperumal K, Natarajan BB, Ramamoorthy MD, Balasubramanian S, Dhiraviam KN. In-silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases. Bioinformation 2015; 11: 73-84.
[17]
Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30: 2785-91.
[18]
Sharma S, Ghosh S, Singh LK, et al. Identification of autoantibodies against transthyretin for the screening and diagnosis of rheumatoid arthritis. PLoS One 2014; 9: e93905.
[19]
Kumar P, Banik S. Pharmacotherapy options in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2013; 6: 35-43.
[20]
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
[21]
Negrei C, Bojinca V, Balanescu A, et al. Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches. Exp Ther Med 2016; 11: 1177-83.
[22]
Shakiba K, Falcone T. Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report. Hum Reprod 2006; 21: 2417-20.
[23]
Gómez-Reino J. Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology 2012; 5: v31-7.
[24]
Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009; 68: 1136-45.

Rights & Permissions Print Cite
Article Metrics
72
4
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy